Prazosin in the treatment of chronic asthma.
The role of prazosin, an alpha 1 adrenoceptor blocker, was investigated in patients with chronic stable asthma who continued to have symptoms despite conventional treatment. Forty patients were entered into a double blind, placebo controlled, crossover trial to examine the effect of adding oral prazosin (2 mg twice daily) to previous medication for three weeks. Sixteen patients withdrew from the study. The remaining 24 patients showed no significant change in peak expiratory flow, FEV1, forced vital capacity (FVC), FEV1/FVC ratio, diary card symptom scores, or dose of beta sympathomimetic.
Baudouin
S V
SV
Chest Clinic, Kent and Canterbury Hospital.
Aitman
T J
TJ
Johnson
A J
AJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000627:therapeutic use*; D014797:Vital Capacity
D011224:Prazosin